Intelligence Hub
Market analytics and operational performance indicators
144 - May 30, 2025
Rocket Lab officer Frank Klein to sell 44,885 shares (~$1.2M) for tax obligations.
Brief
Form 144 filed by Rocket Lab officer Frank Klein discloses intent to sell 44,885 common shares valued at $1,196,672 on May 30, 2025. Shares stem from vesting of 81,250 restricted stock units on May 22, 2025, as compensation. Sale covers tax liabilities from vesting; recent 3-month sales total 48,957 shares for ~$920k.
Detailed Brief
Rocket Lab USA Inc. officer Frank Klein submitted a Form 144 on May 30, 2025, notifying of a proposed sale of 44,885 common shares through Morgan Stanley, with an aggregate market value of $1,196,672.12 (based on ~$26.66/share) and total shares outstanding of 461,432,393. The securities were acquired on May 22, 2025, via vesting of 81,250 restricted stock units issued as compensation by the issuer.
Over the past three months, Klein sold 48,957 common shares in three transactions: 44,553 shares on March 14, 2025 ($810,031.46), 1,835 on March 17 ($36,571.55), and 2,569 on May 28 ($73,884.44), totaling ~$920,487. The filing notes the sale includes amounts to cover tax obligations from the vested equity award settlement. Klein represents no knowledge of undisclosed material adverse information regarding Rocket Lab's operations.
Key Telemetry
- • Frank Klein (officer) to sell 44,885 common shares ($1,196,672) on 05/30/2025.
- • Shares from 81,250 RSU vesting on 05/22/2025 as compensation.
- • Past 3 months: 48,957 shares sold for ~$920k across 3 trades.
- • Sale covers tax obligations; no material adverse info disclosed.
Impact Vector
Routine executive sale to cover taxes on vested RSUs signals no distress, common in equity-compensated firms like Rocket Lab. Low dilution impact (0.01% of shares outstanding). Investors should watch aggregate insider selling trends and 10b5-1 plans, but this aligns with compensation practices amid RKLB's launch growth; neutral near-term signal.